Move means small-cap won't receive an expected payout in the first quarter, creating a cash overhang Sangamo Therapeutics Inc.'s stock tumbled 53% Tuesday to put it on track for its second-biggest one ...
Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase ...